Cardiovascular DiseasePhase 2NCT04270760

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

A Phase 2 study testing Olpasiran in people with Cardiovascular Disease, run by Amgen at 36 sites in 7 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]). Read more about this study

Who is it for?: Ages 18 to 80 years
Conditions the study is for: Cardiovascular Disease
What is being tested?: Olpasiran
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 281 participants
Where: 36 sitesin 7 countries
Study dates: 28 Jul 2020to 8 Nov 2022
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age 18 to 80 years
Lipoprotein (a) > 150 nmol/L
Evidence of atherosclerotic cardiovascular disease

Who cannot join

Severe renal dysfunction
History or clinical evidence of hepatic dysfunction
Malignancy within the last 5 years
Currently receiving, or less than 3 months at Day 1 since receiving > 200 mg/day Niacin

Trial locations and contacts

36 sites in 7 countries.

Country

City, postcode or hospital

36 sites in 7 countries

United States12 sites

Piedmont Healthcare
Atlanta, Georgia, 30309
Johns Hopkins
Baltimore, Maryland, 21287
Westside Medical Associates of Los Angeles
Beverly Hills, California, 90211
Excel Medical Clinical Trials
Boca Raton, Florida, 33434
Cleveland Clinic
Cleveland, Ohio, 44195
Baylor College of Medicine
Houston, Texas, 77030
Protenium Clinical Research
Hurst, Texas, 76054
University of Kansas Medical Center
Kansas City, Kansas, 66160
Crossroads Clinical Research Inc
Mooresville, North Carolina, 28117
New York University
New York, New York, 10016
Mount Sinai Hospital
New York, New York, 10029
Columbia University Medical Center
New York, New York, 10032

Other trials in United States

Australia5 sites

Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050
Monash Medical Centre
Clayton, Victoria, 3168
Core Research Group Pty Ltd
Milton, Queensland, 4064
Linear Clinical Research Limited
Nedlands, Western Australia, 6009
Dr Heart Pty Ltd
Woolloongabba, 4102

Other trials in Australia

Canada5 sites

LMC Clinical Research Incorporated
Brampton, Ontario, L6S 0C6
Ecogene-21
Chicoutimi, Quebec, G7H 7K9
LMC Clinical Research Incorporated Thornhill
Concord, Ontario, L4K 4M2
Research Institute of McGill University Health Center - Glen Site
Montreal, Quebec, H4A 3J1
Clinique des Maladies Lipidiques de Quebec Incorporated
Québec, Quebec, G1V 4W2

Other trials in Canada

Japan5 sites

Asahi General Hospital
Asahi-shi, Chiba, 289-2511
Asahikawa City Hospital
Asahikawa-shi, Hokkaido, 070-8610
Saitama Medical University Hospital
Iruma-gun, Saitama, 350-0495
Kanazawa Medical University Hospital
Kahoku-gun, Ishikawa-ken, 920-0293
The Jikei University Kashiwa Hospital
Kashiwa-shi, Chiba, 277-8567

Other trials in Japan

Netherlands5 sites

Academisch Medisch Centrum
Amsterdam, 1105 AZ
Rijnstate Ziekenhuis
Arnhem, 6815 AD
Haga Ziekenhuis
The Hague, 2545 AA
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX
VieCuri Medisch Centrum
Venlo, 5912 BL

Other trials in Netherlands

Denmark3 sites

Aarhus Universitetshospital
Aarhus N, 8200
Herlev Gentofte Hospital
Herlev, 2730
Regionshospitalet Viborg
Viborg, 8800

Other trials in Denmark

Iceland1 site

Thjonustumidstod Rannsoknaverkefna
Kopavogur, 201

Other trials in Iceland

About this study

Official title: A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)

Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).

Conditions: Cardiovascular Disease
Being tested: Olpasiran, Placebo
Keywords: Olpasiran, AMG 890, siRNA, lipoprotein (a) Lp(a), Cardiovascular, Cardiovascular disease, Atherosclerotic cardiovascular disease, Cholesterol, Apolipoprotein (B), Hyperlipidemia, Dyslipidemia
Medical subject headings: Cardiovascular Diseases, Atherosclerosis, Hyperlipidemias, Dyslipidemias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

OlpasiranDrug
Also called AMG 890
Dose 1 Dose 2 Dose 3 Dose 4
PlaceboDrug
Dose 5

Study groups in NCT04270760
Study group	Role	What they receive
Arm 1 Olpasiran Dose 1	Active comparator	Not described Receives: Drug: Olpasiran
Arm 2 Olpasiran Dose 2	Active comparator	Not described Receives: Drug: Olpasiran
Arm 3 Olpasiran Dose 3	Active comparator	Not described Receives: Drug: Olpasiran
Arm 4 Olpasiran Dose 4	Active comparator	Not described Receives: Drug: Olpasiran
Arm 5 Placebo Dose 5	Placebo comparator	Not described Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
Measured: Baseline and Week 36

Secondary outcomes (4)

Percentage Change From Baseline in Lp(a) at Week 48
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
Measured: Baseline and Week 48
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 36 and Week 48
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
Measured: Baseline; Week 36 and Week 48
Percentage Change From Baseline in Apolipoprotein (B) (ApoB) at Week 36 and Week 48
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
Measured: Baseline; Week 36 and Week 48
Mean Serum Olpasiran Concentrations at Day 1, Week 24 and Week 48
Pharmacokinetic blood draws were collected at one timepoint during the 6-12 and 24-72 hour flexible time windows and at Week 48.
Lower limit of quantification (LLOQ) = 0.400 ng/mL. Values below the LLOQ were set to zero.
Measured: Pre-dose and 1, 3, 6-12, and 24-72 hours post-dose on Day 1 and Week 24; Week 48

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

28 Jul 20208 Nov 2022

First posted17 Feb 2020
Study start28 Jul 2020
Primary completion27 Dec 2021
Study completion8 Nov 2022

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (7)Papers the sponsor has linked to this study.
Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
More trials run by AmgenThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 281 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04270760
Sponsor's protocol ID: 20180109
Other IDs: 2019-003688-23, 2019
Status last verified: Mar 2026
First submitted: 13 Feb 2020
Last updated: 31 Mar 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Publications

O'Donoghue ML, G Lopez JA, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H, Sabatine MS. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022 Sep;251:61-69. doi: 10.1016/j.ahj.2022.05.004. Epub 2022 May 16.
PubMed 35588897
O'Donoghue ML, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6.
PubMed 36342163
O'Donoghue ML, Rosenson RS, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Murphy SA, Wang H, Wu Y, Shah T, Wang J, Wilmanski T, Sohn W, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results. J Am Coll Cardiol. 2024 Aug 27;84(9):790-797. doi: 10.1016/j.jacc.2024.05.058.
PubMed 39168564
Kaur G, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Park JG, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML. Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study. Eur Heart J. 2025 Mar 24;46(12):1162-1164. doi: 10.1093/eurheartj/ehae781. No abstract available.
PubMed 39565305
Rosenson RS, Lopez JAG, Gaudet D, Baum SJ, Stout E, Lepor NE, Park JG, Murphy SA, Knusel B, Wang J, Wilmanski T, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML; OCEAN(a)-DOSE Trial Investigators. Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial. JAMA Cardiol. 2025 May 1;10(5):482-486. doi: 10.1001/jamacardio.2024.5433.
PubMed 39937508
Zimerman A, Lopez JAG, Rosenson RS, Gaudet D, Baum SJ, Park JG, Wang J, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML. Small-Interfering RNA Olpasiran and Apolipoprotein B Particles. JAMA Cardiol. 2025 Dec 1;10(12):1322-1324. doi: 10.1001/jamacardio.2025.4105.
PubMed 41191372
Karp A, Jacobs M, Barris B, Labkowsky A, Frishman WH. Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities. Cardiol Rev. 2025 Jul-Aug 01;33(4):352-358. doi: 10.1097/CRD.0000000000000667. Epub 2024 Feb 28.
PubMed 38415744

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)

All Cardiovascular Disease trials

Study at a glance

From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
ClinicalTrials.gov ID: NCT04270760
Acronym / sponsor ID: 20180109
Conditions: Cardiovascular Disease
Keywords: Olpasiran, AMG 890, siRNA, lipoprotein (a) Lp(a), Cardiovascular, Cardiovascular disease, Atherosclerotic cardiovascular disease, Cholesterol
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 281 participants (actual)
Lead sponsor: AmgenIndustry (pharma, biotech, devices)
Study start: 28 Jul 2020 (actual)
Primary completion: 27 Dec 2021 (actual)
Study completion: 8 Nov 2022 (actual)
First posted: 17 Feb 2020 (actual)
Results: Posted 23 Aug 2023

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 5

Arm	Type	Receives
Arm 1 Olpasiran Dose 1	Active comparator	Drug: Olpasiran
Arm 2 Olpasiran Dose 2	Active comparator	Drug: Olpasiran
Arm 3 Olpasiran Dose 3	Active comparator	Drug: Olpasiran
Arm 4 Olpasiran Dose 4	Active comparator	Drug: Olpasiran
Arm 5 Placebo Dose 5	Placebo comparator	Drug: Placebo

Who may qualify

Ages: 18 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

Age 18 to 80 years
Lipoprotein (a) > 150 nmol/L
Evidence of atherosclerotic cardiovascular disease

Key exclusion criteria (4 listed)

Severe renal dysfunction
History or clinical evidence of hepatic dysfunction
Malignancy within the last 5 years
Currently receiving, or less than 3 months at Day 1 since receiving > 200 mg/day Niacin

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
OlpasiranAlso: AMG 890Dose 1 Dose 2 Dose 3 Dose 4	Drug	Arm 1 Olpasiran Dose 1, Arm 2 Olpasiran Dose 2, Arm 3 Olpasiran Dose 3, Arm 4 Olpasiran Dose 4
PlaceboDose 5	Drug	Arm 5 Placebo Dose 5

Primary outcome

Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36
Time frame: Baseline and Week 36
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.

4 secondary outcomes

Percentage Change From Baseline in Lp(a) at Week 48
Time frame: Baseline and Week 48
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 36 and Week 48
Time frame: Baseline; Week 36 and Week 48
Percentage Change From Baseline in Apolipoprotein (B) (ApoB) at Week 36 and Week 48
Time frame: Baseline; Week 36 and Week 48
Mean Serum Olpasiran Concentrations at Day 1, Week 24 and Week 48
Time frame: Pre-dose and 1, 3, 6-12, and 24-72 hours post-dose on Day 1 and Week 24; Week 48

Results and safety

Results posted to the registry on 23 Aug 2023, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Group 1: Olpasiran 10 mg Q12W	58	57
Group 2: Olpasiran 75 mg Q12W	58	55
Group 3: Olpasiran 225 mg Q12W	56	52
Group 4: Olpasiran 225 mg Q24W	55	55
Group 5: Placebo Q12W	54	53

Primary outcome: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36

Time frame: Baseline and Week 36. Least squares mean (Standard Error). Unit: Percentage Change in Lp(a)

Measure	Group 1: Olpasiran 10 mg Q12W n = 57	Group 2: Olpasiran 75 mg Q12W n = 57	Group 3: Olpasiran 225 mg Q12W n = 53	Group 4: Olpasiran 225 mg Q24W n = 53	Group 5: Placebo Q12W n = 51
Value	-66.91 (1.78)	-93.78 (1.78)	-97.53 (1.82)	-96.89 (1.85)	3.60 (1.89)

Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W: Treatment difference: -70.51 (95% CI -75.12 to -65.90), p <0.001, Repeated measures linear effects model
Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W: Treatment difference: -97.38 (95% CI -101.98 to -92.77), p <0.001, Repeated measures linear effects model
Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W: Treatment difference: -101.13 (95% CI -105.79 to -96.47), p <0.001, Repeated measures linear effects model

Population analysed: Participants in the FAS with data available at each time point. FAS: includes all randomized participants who received at least one dose of IP.

4 secondary outcomes are reported in the full results.

Adverse events

Time frame: Treatment Period: Median duration was 11.07 months. Extended Safety Follow-up Period: Median duration was 8.56 months.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Group 1; Treatment Period: Olpasiran 10 mg Q12W	3 of 58 (5.2%)	35 of 58 (60.3%)	0 of 58
Group 2; Treatment Period: Olpasiran 75 mg Q12W	3 of 58 (5.2%)	40 of 58 (69%)	0 of 58
Group 3; Treatment Period: Olpasiran 225 mg Q12W	6 of 56 (10.7%)	37 of 56 (66.1%)	0 of 56
Group 4; Treatment Period: Olpasiran 225 mg Q24W	4 of 55 (7.3%)	36 of 55 (65.5%)	0 of 55
Group 5; Treatment Period: Placebo Q12W	8 of 54 (14.8%)	29 of 54 (53.7%)	1 of 54
Group 1; Extended Safety Follow-up Period: Olpasiran 10 mg Q12W	4 of 57 (7%)	18 of 57 (31.6%)	0 of 57
Group 2; Extended Safety Follow-up Period: Olpasiran 75 mg Q12W	2 of 57 (3.5%)	25 of 57 (43.9%)	0 of 57
Group 3; Extended Safety Follow-up Period: Olpasiran 225 mg Q12W	6 of 54 (11.1%)	21 of 54 (38.9%)	0 of 54
Group 4; Extended Safety Follow-up Period: Olpasiran 225 mg Q24W	5 of 55 (9.1%)	17 of 55 (30.9%)	0 of 55
Group 5; Extended Safety Follow-up: Placebo Q12W	4 of 53 (7.5%)	17 of 53 (32.1%)	0 of 53

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Background: PubMed 35588897O'Donoghue ML, G Lopez JA, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H, Sabatine MS. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022 Sep;251:61-69. doi: 10.1016/j.ahj.2022.05.004. Epub 2022 May 16.
Background: PubMed 36342163O'Donoghue ML, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6.
Background: PubMed 39168564O'Donoghue ML, Rosenson RS, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Murphy SA, Wang H, Wu Y, Shah T, Wang J, Wilmanski T, Sohn W, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results. J Am Coll Cardiol. 2024 Aug 27;84(9):790-797. doi: 10.1016/j.jacc.2024.05.058.
Background: PubMed 39565305Kaur G, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Park JG, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML. Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study. Eur Heart J. 2025 Mar 24;46(12):1162-1164. doi: 10.1093/eurheartj/ehae781. No abstract available.
Background: PubMed 39937508Rosenson RS, Lopez JAG, Gaudet D, Baum SJ, Stout E, Lepor NE, Park JG, Murphy SA, Knusel B, Wang J, Wilmanski T, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML; OCEAN(a)-DOSE Trial Investigators. Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial. JAMA Cardiol. 2025 May 1;10(5):482-486. doi: 10.1001/jamacardio.2024.5433.
Background: PubMed 41191372Zimerman A, Lopez JAG, Rosenson RS, Gaudet D, Baum SJ, Park JG, Wang J, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML. Small-Interfering RNA Olpasiran and Apolipoprotein B Particles. JAMA Cardiol. 2025 Dec 1;10(12):1322-1324. doi: 10.1001/jamacardio.2025.4105.
Derived from this study: PubMed 38415744Karp A, Jacobs M, Barris B, Labkowsky A, Frishman WH. Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities. Cardiol Rev. 2025 Jul-Aug 01;33(4):352-358. doi: 10.1097/CRD.0000000000000667. Epub 2024 Feb 28.
AmgenTrials clinical trials websiteLink provided by the sponsor.
Individual participant dataSharing planned: Yes. De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Related trials for Cardiovascular Disease

Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

MD study director

Amgen

36 sites in 7 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Olpasiran in people with Cardiovascular Disease, run by Amgen at 36 sites in 7 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 36 sites in United States, Australia, Canada, Japan, Netherlands and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Aug 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (time frame: Baseline and Week 36). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04270760, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.